Decitabine (NSC 127716)

Name: Decitabine (NSC 127716)
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (102 reviews)

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

102 publications

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Selleck's Decitabine (NSC 127716) has been cited by 102 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

J Immunother Cancer, 2021, 9(7)e002528

PubMed: 34321275 ( click the link to review the publication )

Cancer Lett, 2021, 507:26-38

PubMed: 33713739 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):532

PubMed: 34031358 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):90

PubMed: 33941774 ( click the link to review the publication )

Front Oncol, 2021, 11:639408

PubMed: 34094922 ( click the link to review the publication )

Front Oncol, 2021, 11:668798

PubMed: 34079760 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2424

PubMed: 33510302 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00538-5

PubMed: 33932446 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Biotechnol Lett, 2021, 10.1007/s10529-021-03112-2

PubMed: 33788127 ( click the link to review the publication )

Nat Commun, 2020, 6;11(1):740

PubMed: 32029739 ( click the link to review the publication )

Oncogene, 2020, 11

PubMed: 32393833 ( click the link to review the publication )

PLoS Genet, 2020, 16(11):e1009159

PubMed: 33175846 ( click the link to review the publication )

J Cancer, 2020, 28;11(10):2874-2886

PubMed: 32226505 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

JCI Insight, 2020, 5(11):e137569

PubMed: 32493845 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11396

PubMed: 32647280 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30632-7

PubMed: 33253790 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Genet Test Mol Biomarkers, 2020, 24(7):399-408

PubMed: 32551898 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:6665-6677

PubMed: 32801900 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 10.1111/1440-1681.13390

PubMed: 32754907 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3461-3475

PubMed: 32774712 ( click the link to review the publication )

Mol Ther Oncolytics, 2020, 18:282-294

PubMed: 32728616 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007578

PubMed: 30699189 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )
ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 218:241-252

PubMed: 30586565 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1007-1018

PubMed: 30431129 ( click the link to review the publication )

Dis Markers, 2019, 2019:9175215

PubMed: 31558918 ( click the link to review the publication )

Mol Psychiatry, 2019, 10.1038/s41380-019-0588-9

PubMed: 31745236 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )
J Cancer, 2018, 9(16):2807-2816

PubMed: 30123349 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

Sci Rep, 2017, 7:40762

PubMed: 28094306 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )
Cancer Immunol Res, 2015, 3(9):1030-41

PubMed: 26056145 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	MX3GeY5kfGmxbjDBd5NigQ>?	MXOwMlXDqM7:TR?=	MkW5NlQhcA>?	NXqze5k4f2G2ZYK=	MknHcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM>	NY\pcJJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109	NXHrZXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkH6NE42NzJwNT:1JO69VQ>?	Mon3NlQwPDhxN{KgbC=>	MVj3ZZRmeg>?	NV3IOYl2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	MojRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109	MXzGeY5kfGmxbjDBd5NigQ>?	MmHPNE42yqEQvF2=	Ml3FOk8yOi9{NDDo	M2GzWJdifGW{	NGTtc4xqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109	MknoSpVv[3Srb36gRZN{[Xl?	MWGwMlXDqM7:TR?=	MVWyOEBp	MYT3ZZRmeg>?	M4\pRolvcGmkaYTzJINmdGxiaX72ZZNqd25?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO1[osxNjYEoN88US=>	M{XwfVI1KGh?	MV\3ZZRmeg>?	M3jVNIlv\HWlZYOgS\|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU>	M{ji[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN\|A5OjxxYU6=
Eca109	NUH5XZZwTnWwY4Tpc44hSXO\|YYm=	MWSwMlUwOSEQvF2=	MlvGNlQhcA>?	MVf3ZZRmeg>?	M1\xZYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ?	MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116	NVPPZYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nNSVAvPS9zL{KvOUDPxE1?	M4DtPFQ5KGh?	MlzmSG1UVw>?	MYHlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u	NH\wTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O\|QzQDZ:L3G+
LOVO	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGzNE42NzFxMj:1JO69VQ>?	NIDzTGo1QCCq	M{O4PWROW09?	MkP1[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116	MVjGeY5kfGmxbjDBd5NigQ>?	NV;zcIZoOTBizszN	MVi0PEBp	NIXaPFNFVVOR	M4XqdYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO	NGf0fXJHfW6ldHnvckBCe3OjeR?=	NXrjbGRlOTBizszN	M{XBdVQ5KGh?	NUfUNJJlTE2VTx?=	M1jYfolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>?	M1T4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
SW1116	MWXBdI9xfG:\|aYOgRZN{[Xl?	NVrJR5VyOTBizszN	M4HXOVQ5KGh?	NYeze3lETE2VTx?=	MlW0[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz	NYryTlhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO	MWDBdI9xfG:\|aYOgRZN{[Xl?	NILi[WcyOCEQvF2=	NWrMNIRoPDhiaB?=	M1zKTGROW09?	NYm0c5pr\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{	M1TPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
RPMI-8226	MofXRZBweHSxc3nzJGF{e2G7	M{\RdVEwOiEQvF2=	NEPKcpc1QC95Mj:5OkBp	MoTqSG1UVw>?	NWGzSoNRcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M4Pa[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
OPM-2	MU\BdI9xfG:\|aYOgRZN{[Xl?	NFfhW44yNzJizszN	MXG3Nk86Pi9zMkCgbC=>	MnqySG1UVw>?	MXjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3u3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
JJN3	MnfCRZBweHSxc3nzJGF{e2G7	MX6wMlUwOSEQvF2=	M33xb\|I1NzR6IHi=	MoTmSG1UVw>?	M1rx[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NHjTW\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN\|ExQCd-MkS4N\|MyODh:L3G+
NCI-H929	M1X0R2Fxd3C2b4Ppd{BCe3OjeR?=	NUXQXVFDOS9{IN88US=>	NGXZWGM4Oi97Nj:xNlAhcA>?	NH;VfWtFVVOR	NU\OcFZtcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M4fZ[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
RPMI-8226	NHXnSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13tTFEwOiEQvF2=	M2Lyd\|I1NzR6L{eyJIg>	NFuxRW5FVVOR	M1r2ZYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	NIP4Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN\|ExQCd-MkS4N\|MyODh:L3G+
OPM-2	NYH4V2lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHOWmwyNzJizszN	MnPTNlQwPDhxN{KgbC=>	M2C2VGROW09?	NXT4dopD[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3	NFH0ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXTO5YxNjVxMTFOwG0>	M2flTlI1NzR6L{eyJIg>	MXHEUXNQ	M2DRUoFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	NVnIbnpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlztNU8zKM7:TR?=	MWiyOE81QC95MjDo	NFjTRllFVVOR	NUnpblNH[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa	M2m0d2tqdmG\|ZTDBd5NigQ>?				MlfKT4k:OTByMPMAl\|UxODBizszNJIZweiCqRV7UNS=>	MmnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
HeLa	NX;2NmM5U2mwYYPlJGF{e2G7				M33reGtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=>	NXnYeINxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O\|gxODl6PD;hQi=>
HeLa	MWTLbY5ie2ViQYPzZZk>				NWLUTmtvU2l;MkGuOkDDuSB\|LkCg{txOKG[xcjDoR25VOQ>?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
HeLa	MWPLbY5ie2ViQYPzZZk>				MUnLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz	NEDlZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
NB4	M1fhd2Z2dmO2aX;uJGF{e2G7	M2X0[lIvPS93L{euOU8yOCEQvF2=	MXyyOEBp	MXPEUXNQ	Mk[zbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NEi3NEc,OjR2OES4O\|A9N2F-
CD4+ CD25− T	NUP5PIZQTnWwY4Tpc44hSXO\|YYm=	M{HaTVEwPSEQvF2=			M1TwVJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	M1P0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe2N\|YxLz5{NES3OlM3ODxxYU6=
BV-173	MV3BdI9xfG:\|aYOgRZN{[Xl?	NXzV[HVsOC5{NT:wMlUwOC55NT:xJO69VQ>?	Mn7WOFgwPzJxOU[gbC=>	NVvqblRlyqCSQmO=	M37tbolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	NHLwPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
ML-1	NULKeoNHSXCxcITvd4l{KEG\|c3H5	Mn3rNE4zPS9yLkWvNE44PS9zIN88US=>	MoXsOFgwPzJxOU[gbC=>	M2SxeeKhWEKV	NIDhOoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60	NE\HOYVCeG:ydH;zbZMhSXO\|YYm=	NVLR[o1VOC5{NT:wMlUwOC55NT:xJO69VQ>?	NXLKO\|NUPDhxN{KvPVYhcA>?	NYfaNVRVyqCSQmO=	NE\nWGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
KG-1a	M1TxXmFxd3C2b4Ppd{BCe3OjeR?=	Mn7aNE4zPS9yLkWvNE44PS9zIN88US=>	MWK0PE84Oi97NjDo	MUJCpHBDWw>?	MVHpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NH\ueFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
BV-173	NXXCUJJNTnWwY4Tpc44hSXO\|YYm=	MUWyOVAwPTBybl2=	NX;DZXRMPDhiaB?=	Ml\lxsBRSlN?	NFzLVFJqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	NGLyVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
CEM	NYLrVGI6TnWwY4Tpc44hSXO\|YYm=	NYq2T49NOjVyL{WwNI5O	M2qzfVQ5KGh?	M{jiZuKhWEKV	MonybY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60	MWLGeY5kfGmxbjDBd5NigQ>?	M{HRU\|I2OC93MEDuUS=>	M4jxU\|Q5KGh?	Mnm4xsBRSlN?	NFv1NmRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	NI\UfZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
ML-1	Mor3SpVv[3Srb36gRZN{[Xl?	Mnq4NlUxNzVyMH7N	MWq0PEBp	MmrFxsBRSlN?	NHrIPZNqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	NELqfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
DLD-1	M4LmcWZ2dmO2aX;uJGF{e2G7	M1vvdFI2OC93MEDuUS=>	M{e5Z\|Q5KGh?	MYhCpHBDWw>?	NEDIOJBldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	NFL5PHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
HCT-116	NX\6dmt6TnWwY4Tpc44hSXO\|YYm=	NVr6[HhROjVyL{WwNI5O	NIP2R2c1QCCq	NHXGXlPDqFCEUx?=	NFG1WoRldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	NIqzepU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
U937-A/E-9/14/18	NHftS3VCeG:ydH;zbZMhSXO\|YYm=	MYCwMlAyNzBwMT:xM\|ExKM7:TR?=	NITLVJg1QCCq		MnnjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIXCdXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOwNFQ2Pid-MkSzNFA1PTZ:L3G+
HT29	NF73RZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NU\PfFZHPzJiaB?=		NWXZd28{UUN3ME2xOFAxyrFzN{mg{txO	M4DEVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
SW48	NH7Me\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF;Nc5k4OiCq		M{\uXGlEPTB;MUWuNuKyPi5{IN88US=>	NU\iNmRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|IxPjFpPkK0NVczODZzPD;hQi=>
HCT116	NGfOVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NITjZpo4OiCq		NIS0dJpKSzVyPUGuO:KyOC52IN88US=>	MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
HepG2	M2DE[mZ2dmO2aX;uJGF{e2G7	NEX4fVUxNjVxMTFOwG0>	NXrjNXJrOjRiaB?=	MVTEUXNQ	M1WzbpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	M3vyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T	NEPEPJpHfW6ldHnvckBCe3OjeR?=	NFjPfXoxNjVxMTFOwG0>	MkH6NlQhcA>?	NXvxO3p7TE2VTx?=	MnP2cIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO=	M2D0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2	NXexUItOSXCxcITvd4l{KEG\|c3H5	MY[xM\|ExNzFyMDFOwG0>	M2G4[Vch\A>?	NXzmT4RnTE2VTx?=	MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
LS174T	M4PPR2Fxd3C2b4Ppd{BCe3OjeR?=	M2LvTFEwOTBxMUCwJO69VQ>?	M1roe\|ch\A>?	NYD4elgzTE2VTx?=	NF:4TXdqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M2XvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939	NHq5U45CeG:ydH;zbZMhSXO\|YYm=	MX:xM\|ExNzFyMDFOwG0>	MWW3JIQ>	NEDoU2ZFVVOR	MWHpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O\|Q9N2F-
U251	NGDLPG5CeG:ydH;zbZMhSXO\|YYm=	MmjkNU8yOC9zMECg{txO	M4Tjb\|ch\A>?	MV3EUXNQ	MYLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NVHMO4pbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HL-60	M1qzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnGVlRyOSEQvF2=	Mk[4OFghcA>?		MX\pcoNz\WG\|ZYOgS\|IueGijc3WgZ4VtdCCocnHjeIlwdg>?	MkLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMECzNlQoRjJ2MECwN\|I1RC:jPh?=
MDA‑MB‑453	M4HTcGZ2dmO2aX;uJGF{e2G7	M1\6dFAvOi9zIN88US=>	MYS3NkBp		MX7jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	NUjjRnZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
HCC1569	M3\zTWZ2dmO2aX;uJGF{e2G7	M4XVNVAvOi9zIN88US=>	MlPkO\|IhcA>?		MV\jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	M4XGflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
BT‑474	NGPRWGRHfW6ldHnvckBCe3OjeR?=	NFnaT2YxNjJxMTFOwG0>	NGm3XlQ4OiCq		MWHjZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	NI\YR\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFIzQCd-MkO4OFQzOjh:L3G+
AGS	MnrORZBweHSxc3nzJGF{e2G7	M3TOdVUwOTBxMkCvOVAh\|ryP	MXy0POKhcMLi	MmjiSG1UVw>?	MWDpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	M13oRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUiyO\|g1Lz5{M{W4Nlc5PDxxYU6=
A549	M{HudGFxd3C2b4Ppd{BCe3OjeR?=	NV\JenYxPS9zMD:yNE82OCEQvF2=	MV60POKhcMLi	NXf5bIpITE2VTx?=	MoG1bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA>	M4XmNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUiyO\|g1Lz5{M{W4Nlc5PDxxYU6=
AGS	M{TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoT0OU8yOC9{MD:1NEDPxE1?	NVH6d\|NDPDkEoHlCpC=>	MojESG1UVw>?	NFXPbVlqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA>	M4L4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUiyO\|g1Lz5{M{W4Nlc5PDxxYU6=
Kasumi-1	NX3NNYlZSXCxcITvd4l{KEG\|c3H5	NUDo[IlMOC53IN88US=>	Mn\SOFjDqGkEoB?=		MWfk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2\|Yx?=	MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ\|NEmzN\|Q5RC:jPh?=
OCI-AML3	MknaRZBweHSxc3nzJGF{e2G7	M1nmdFIvPSEQvF2=	MkfiOFjDqGkEoB?=		M1HpWoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	M1zTblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzN\|Q5Lz5{M{S5N\|M1QDxxYU6=
MV4-11	NFW0OlFCeG:ydH;zbZMhSXO\|YYm=	NHLMNFczNjVizszN	NIfob4o1QMLiaNMg		MmX4[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	M{HkVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEmzN\|Q5Lz5{M{S5N\|M1QDxxYU6=
NK	M4[1SWN6fG:2b4jpeJkhSXO\|YYm=	MlexNE4xOi1{MDFOwG0>	NXr5OYkzPSCm		MmLV[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26\|ZTDjeZJ3\Q>?	NULifYFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgxQDhpPkKzN\|I5ODh6PD;hQi=>
NK	NGLrZ5VCeG:ydH;zbZMhSXO\|YYm=	M2HiNFAvODJvMkCg{txO	NFHKdVY2KGR?		M4nBToRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>?	MnS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkiwPFgoRjJ\|M{K4NFg5RC:jPh?=
NK	NHXwRXNHfW6ldHnvckBCe3OjeR?=	MnT6NE4xOS1{MDFOwG0>	Mm\WOUBl		NUe3ZXF3[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>?	NF7xPFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
MOLT4/DNR	NEDwPI1HfW6ldHnvckBCe3OjeR?=	NEW0VpE2KM7:TR?=	MmTnOEBl		MYXy[YR2[2W\|IFHCR2IyKG2UTlGg[ZhxemW\|c3nvci=>	NW\SWJN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX	MmjKSpVv[3Srb36gRZN{[Xl?	M4HrblUh\|ryP	M1\aelQh\A>?		MX\y[YR2[2W\|IFHCR2IyKG2UTlGg[ZhxemW\|c3nvci=>	NYDvU\|E6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
MOLT4/DNR	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVe1JO69VQ>?	NWfJeGl1PCCm		MYTy[YR2[2W\|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O\|A9N2F-
Jurkat/DOX	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEH4dHE2KM7:TR?=	NV\mW2NWPCCm		MlPNdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	NE\rN4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
ccRCC	MmLHRZBweHSxc3nzJGF{e2G7	MoXpNE4xOS1zMN88US=>	NVzPRXBrPzJiaB?=	NEDkRo9FVVOR	MmP3bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>?	M4\H[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
TNBC	NEXTUIRCeG:ydH;zbZMhSXO\|YYm=	M1S5R\|AvODFvMUFOwG0>	MUO3NkBp	NWXwZmltTE2VTx?=	MYLoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498	Mn3kRZBweHSxc3nzJGF{e2G7	MX2wMlAyNTFyzszN	NVTI[XQ4PzJiaB?=	NE\ibY5FVVOR	NE\Gc2RqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	M{LURVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
KIJ265T	MlmzRZBweHSxc3nzJGF{e2G7	MoTWNE4xOS1zMN88US=>	MYS3NkBp	NVr5T2xOTE2VTx?=	MkOybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	M4LNdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
MDA-231	MWTBdI9xfG:\|aYOgRZN{[Xl?	Mk\HNE4xOS1zMN88US=>	NFLETVM4OiCq	MmTmSG1UVw>?	M4LlN4lv\HWlZYOgd5lv\XKpaYP0bYMhemW\|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
BT-20	MnfnRZBweHSxc3nzJGF{e2G7	NFv0R5MxNjBzLUGw{txO	MmnBO\|IhcA>?	NEfHfFdFVVOR	NEHtbINqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937	NIjwdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUK1MVIxKM7:TR?=	NUTGWnpCOjRxNEivO\|IhcA>?		NFTDTHpqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60	M1;EO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T3PFUuOjBizszN	M13rTVI1NzR6L{eyJIg>		M{jpZYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
U937	NXnvNmI4SXCxcITvd4l{KEG\|c3H5	NHHXd3gyPSEQvF2=	NUezd3BYOjRxNEivO\|IhcA>?		MnvQbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60	MkjPRZBweHSxc3nzJGF{e2G7	MUexOUDPxE1?	NVzqS5N4OjRxNEivO\|IhcA>?		NXTOVZpGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
LS411N	Mk\ERZBweHSxc3nzJGF{e2G7	MWewMlUh\|ryP	MkfOO\|IhcA>?		NYToNFg6cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs	M3nUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NE[xOlk2Lz5{MkS2NVY6PTxxYU6=
MDA-MB-231	MlrIRZBweHSxc3nzJGF{e2G7	NIHu[mcyOCEQvF2=	Moi3OFghcA>?		M1zRepJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M33POFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O\|Y6PzxxYU6=
MCF-7	NHLNcpdCeG:ydH;zbZMhSXO\|YYm=	MX:xNEDPxE1?	NH\VR3o1QCCq		MXLy[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NVuw[5JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
A375	NEKzWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnmc4ExNjVizszN	NXzFS2N3OS93L{ig[C=>		MkjjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	NFrVfY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nZXlAvPSEQvF2=	MWqxM\|UwQCCm		MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	M33MZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL3	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jlXlAvPSEQvF2=	NFP3[JoyNzVxODDk		NYj0NppEcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28	M33iSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPkNE42KM7:TR?=	M2DtVVEwPS96IHS=		MUXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	Mmn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
MeWo	NVL2OFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LaZ\|AvPSEQvF2=	M{S4V\|EwPS96IHS=		NUXKTXNrcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	M33FPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
B16	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfMflgxNjVizszN	NGLGUXIyNzVxODDk		NWXnXFNDcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NI[wPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
Ly 1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1LlRVI1KGh?		MXTJR\|UxRTdwMzFOwG0>	M3nBO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 7	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4[5bFI1KGh?		NIrOUYZKSzVyPUGwMlch\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6	NV7UTJpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVGyOEBp		NVSyUHpTUUN3MP-8olIxKM7:TR?=	M4XvN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10	NEm5VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LJbFI1KGh?		MoPZTWM2OO,:nkKwJO69VQ>?	NEGyXmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
RIVA	NWjzdmVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYqyOEBp		NXjNOI9NUUN3MP-8olIxKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	NVTKfFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWH6bFh5OjRiaB?=		MX\JR\|Ux97zgMkCg{txO	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1	M4TE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{TPeFQ5KGh?		MYrJR\|UxRTBwM{Sg{txO	MkjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIDNZVY1QCCq		Ml3JTWM2OD1yLkCyOUDPxE1?	Mmr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmrLOFghcA>?		NYXXb2ZCUUN3MP-8olIxKM7:TR?=	MlS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10	NVPBdmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1zSUFQ5KGh?		NW\ydmo4UUN3ME2xMlgh\|ryP	NUWxW3dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
RIVA	M3HGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2Pyc\|Q5KGh?		M4LZPGlEPTExvK6yNEDPxE1?	M2DnfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2	NEnQTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvZbHlxPDhiaB?=		MYPJR\|UxRTF5LkSg{txO	Ml[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrv[VNwPzJiaB?=		MVXJR\|UxRTBwMEGg{txO	NUPGdoE1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 7	NWrodI86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\EUVczKGh?		MU\JR\|UxRTBwMEG4JO69VQ>?	NVW5S\|I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Su-DHL6	NXroW4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2DF[\|czKGh?		M3PPdmlEPTB;MT62JO69VQ>?	NYTVdYZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 10	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGj3W4s4OiCq		Mo\TTWM2OD1zLkKg{txO	M{ni[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA	NVLQPWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3u5cFczKGh?		NFLMPIpKSzVy78{eNlAh\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	NYHM[m16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml7zO\|IhcA>?		MYTJR\|UxRTFzLkKg{txO	M2rPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
U373-MAGI	M{\kWWFvfGm4aYLhcEBie3OjeR?=	NFyy[noxNjJ3IITvJFghfU1?	NFf0d4ozKHSxIEeyJIhzew>?		MkG1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDVOU1o[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI	M4nZUGFvfGm4aYLhcEBie3OjeR?=	NFTMSZcxNjJ3IITvJFghfU1?	NHzId2QzKHSxIEeyJIhzew>?		MlviRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDnZYchdGW4ZXygZZQhOC5{NTD0c{A5KHWPIHHmeIVzKDJidH:gO\|IhcHK\|IHL5JJFRS1JibXX0bI9l	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine (NSC 127716) SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04985656	Not yet recruiting	Drug: Pevonedistat\|Drug: Decitabine\|Drug: Cedazuridine	Myelodysplastic Syndromes (MDS)	Takeda	October 1 2021	Phase 2
NCT04854889	Recruiting	Drug: Decitabine	Refractory Aplastic Anemia	Institute of Hematology & Blood Diseases Hospital	April 22 2021	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine (NSC 127716)